Project Grant R21CA303219
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$471K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This National Institutes of Health National Cancer Institute Project Grant of $470,532 provides funding from July 1, 2022 to June 30, 2027 to Brigham and Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to characterize immunometabolic pathways enabled by PARP inhibition in breast cancer. The grant aims to (1) define the mechanisms by which PARP inhibitors induce lipogenic tumor-associated macrophage development, (2) determine how lipogenic macrophages suppress...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $633,705 to the Mayo Clinic in Rochester, Minnesota to investigate mechanisms underlying resistance to PARP inhibitor (PARPi) drugs in prostate cancer. The research aims to identify strategies to overcome PARPi resistance, with a focus on the role of the NSD3S histone methyltransferase isoform in regulating DNA replication dynamics and contributing to PARPi resistance. The award...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
This federal Project Grant award of $1,598,801.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a Phase 1B study of the BCL-XL degrader DT2216 combined with paclitaxel for the treatment of recurrent platinum-resistant ovarian cancer. The study is being conducted by the Dana-Farber Cancer Institute, Inc., a renowned non-profit cancer research and treatment center in Boston, Massachusetts. The award period runs from July 1, 2025...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $727,732 to conduct research aimed at overcoming resistance to CDK4/6 inhibitor therapy for patients with dedifferentiated liposarcoma. The key objectives are to evaluate the efficacy of combining the CDK4/6 inhibitor palbociclib with the MEK inhibitor mirdametinib in a Phase Ib/II clinical trial, and to analyze the molecular...
The Department of Defense (DoD) has awarded a $846,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Institute For Cancer Research, a non-profit research organization, to investigate PALB2 mutant breast cancer. The funding supports a 3-year research project from August 1, 2024 to July 31, 2027. As the prime grantee, The Institute For Cancer Research will conduct innovative scientific studies and clinical trials focused on developing new treatments...
This federal Project Grant award for $716,314.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop novel therapeutics targeting FGFR2 alterations in gastroesophageal adenocarcinoma (GEA). The key products and services to be delivered include: Utilizing novel immune-competent mouse models of FGFR2-altered GEA to develop and test highly efficacious FGFR2 biparatopic antibodies (BIPABs) and FGFR2-targeted antibody-drug conjugates (ADCs), alone or in...
This federal Project Grant award of $518,700.00 was made by the Defense Health Agency on July 1, 2024 to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, MA. The award is part of the Military Medical Research and Development (CFDA 12.420) program, which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the broader public. The funding will support Bidmc's project titled "EXPLOITING DISRUPTION IN TRANSCRIPTIONAL...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $527,159 in funding to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to conduct research on the role of DNA damage and cell fate plasticity in the initiation of BRCA1-related basal-like breast cancer. The key objectives of the research are to: 1) study whether BRCA1-deficient luminal mammary cells acquire a fetal mammary stem cell-like gene expression program...